References
- Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276–85
- Franke HR, Kole S, Ciftci Z, Haanen C, Vermes I. In vitro effects of estradiol, dydrogesterone, tamoxifen and cyclophosphamide on prolifera-tion vs. death in human breast cancer cells. Cancer Lett 2003;190:113–18
- Dew JE, Wren BG, Eden JA. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study. Climacteric 2002;5:151–5
- Habel LA, Stanford JL. Hormone receptors and breast cancer. Epidemiol Rev 1993;15:209–19
- Di Saia PJ. Hormone replacement therapy for breast cancer survivors: facts versus fears. Clin Oncol 1995;7:241–5
- Riggs BL, Hartmann LC. Selective estrogen-receptor modulators—mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618–29
- Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in post menopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treatment 2001;65:125–34
- Dew JE, Eden JA. Gynaecological complications of women treated with tamoxifen for breast cancer. Aust NZ Obstet Gynaecol 1995;35:198–200
- Canney PA, Hatton MQF. The prevalence of menopausal symptoms in women treated for breast cancer. Clin Oncol 1994;6:297–9
- Baum M, Buzdar AU, Cuzick J, et al. Anastro-zole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast can-cer: First results of the ATAC randomised trial. Lancet 2002;359:1231–9
- Cobleigh MA, Berris RF, Bush T, et al. Estrogen replacement therapy in breast cancer survivors. JAMA 1994;272:540–5
- Rose C, Mouridsen HT. Endocrine management of advanced breast cancer. Horm Res 1989;32(Suppl 1):189–97
- Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451–67
- Gompel A, Chaouat M, Jacob D, Perrot JY, Kloosterboer HJ, Rostene W. In vitro studies of tibolone in breast cancer. Fertil Steril 2002;78:351–9
- Marx PTJ, Mulder AB, Bergh van den FAJTM, Overbeeke R, Haanen C, Vermes I. Apoptosis inducers endotoxin and Fas-ligation enhance the expression of vascular endothelial growth factor in human endothelial cells. Endothelium 1999;6:335–40
- Nicoletti I, Migliorati G, Pagliacci MC, Grigna-ni F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;138:271–9
- Vermes I, Haanen C, Reutelingsperger C. Flow cytometry of apoptotic cell death. J Immunol Methods 2000;243:167–90
- Seeger H, Wallwiener D, Mueck AO. Compar-ison of the effect of progesterone, medroxyprogesterone acetate and norethister-one on the proliferation of human breast cancer cells. J Br Menopause Soc 2003:9:36–8
- Sutherland RL, Hall RE, Pang GY, Musgrove EA, Clarke CL. Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. Cancer Res 1988;48:5084–91
- Holmberg L, Anderson H. Habits (hormone replacement therapy after breast cancer — is it safe?), a randomised comparison: trial stopped. Lancet 2004;363:453–5